Abnormal function of the vasopressin-cyclic-AMP-aquaporin2 axis during urine concentrating and diluting in patients with reduced renal function. A case control study

BMC Nephrology

Volumn 11, Issue 1, 2010, Pages

  Pedersen, Erling B ^a,b   Thomsen, Ingrid M ^a   Lauridsen, Thomas G ^a  

^a HOLSTEBRO HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 2; CYCLIC AMP; VASOPRESSIN; ARGIPRESSIN;

ADULT; AGED; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FREE WATER CLEARANCE; GLOMERULUS FILTRATION RATE; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY CONCENTRATING CAPACITY; KIDNEY DILUTING CAPACITY; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE FUNCTION; MALE; NEPHROSCLEROSIS; URINARY EXCRETION; URINE OSMOLALITY; URINE VOLUME; WATER LOADING; ADOLESCENT; BLOOD; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; MIDDLE AGED; OSMOLARITY; PATHOPHYSIOLOGY; PHYSIOLOGY; REFERENCE VALUE; URINALYSIS; URINE;

ADOLESCENT; ADULT; AGED; AQUAPORIN 2; ARGININE VASOPRESSIN; CASE-CONTROL STUDIES; CYCLIC AMP; FEMALE; HUMANS; KIDNEY CONCENTRATING ABILITY; MALE; MIDDLE AGED; OSMOLAR CONCENTRATION; REFERENCE VALUES; RENAL INSUFFICIENCY, CHRONIC; URINALYSIS; YOUNG ADULT;

EID: 77957287191     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-11-26     Document Type: Article

References (35)

1. Physiology and pathophysiology of renal aquaporins. TH Kwon H Hager LN Nejsum ML Andersen J Frøkiaer S Nielsen, Semin Nephrol 2001 21 231 238 10.1053/snep.2001.21647 11320486
2. Aquaporins in the kidney: from molecules to medicine. S Nielsen J Frokiaer D Marples TH Kwon P Agre MA Knepper, Physiol Rev 2002 82 205 244 11773613
3. Molecular mechanisms of clinical concentrating and diluting disorders. RW Schrier, Prog Brain Res 2008 170 539 550 full-text 18655907
4. Nonosmotic release of vasopressin and renal aquaporins in impaired urinary dilution in hypothyroidism. YC Chen MA Cadnapaphornchai J Yang SN Summer S Falk C Li W Wang RW Schrier, Am J Physiol Renal Physiol 2005 289 672 678 10.1152/ajprenal.00384.2004 15914774
5. Molecular mechanisms of impaired urinary concentrating ability in glucocorticoid-deficient rats. YC Chen MA Cadnapaphornchai SN Summer S Falk C Li W Wang RW Schrier, J Am Soc Nephrol 2005 16 2864 2871 10.1681/ASN.2004110944 16107579
6. Molecular analysis of impaired urinary diluting capacity in glucocorticoid deficiency. W Wang C Li SN Summer S Falk MA Cadnapaphornchai YC Chen RW Schrier, Am J Physiol Renal Physiol 2006 290 1135 1142 10.1152/ajprenal.00356.2005 16352742
7. Polyuria of thyrotoxicosis: downregulation of aquaporin water channels and increased solute excretion. W Wang C Li SN Summer S Falk RW Schrier, Kidney Int 2007 72 1088 1094 10.1038/sj.ki.5002475 17700641
8. Downregulation of UT-A1/UT-A3 is associated with urinary concentrating defect in glucocorticoid-excess state. C Li W Wang SN Summer S Falk RW Schrier, J Am Soc Nephrol 2008 19 1975 1981 10.1681/ASN.2008010051 18667732
9. Renal concentrating and diluting function in deficiency of specific aquaporin genes. AS Verkman, Exp Nephrol 2002 10 235 240 10.1159/000063697 12097826
10. Severe urinary concentrating defect in renal collecting duct-selective AQP2 conditional-knockout mice. A Rojek EM Füchtbauer TH Kwon J Frøkiaer S Nielsen, Proc Natl Acad Sci USA 2006 103 6037 6042 10.1073/pnas.0511324103 16581908
11. Urea and urine concentrating ability in mice lacking AQP1 and AQP3. D Zhao L Bankir L Qian D Yang B Yang, Am J Physiol Renal Physiol 2006 29 429 438 10.1152/ajprenal.00011.2006 (Pubitemid 44148133)
12. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). AS Levey KU Eckardt Y Tsukamoto A Levin J Coresh J Rossert D De Zeeuw TH Hostetter N Lameire G Eknoyan, Kidney Int 2005 67 2089 2100 10.1111/j.1523-1755.2005.00365.x 15882252
13. Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans. RS Pedersen H Bentzen JN Bech EB Pedersen, Am J Physiol Renal Physiol 2001 280 860 F867 11292629
14. Effect of captopril on renal extraction of renin, angiotensin II, atrial natriuretic peptide and vasopressin, and renal vein renin ratio in patients with arterial hypertension and unilateral renal artery disease. EB Pedersen H Eiskjaer B Madsen H Danielsen M Egeblad CB Nielsen, Nephrol Dial Transplant 1993 8 1064 1070 8272217
15. Influence of range of renal function and liver disease on predictability of creatinine clearance. JH Hull LJ Halk GG Koch WA Wargin SL Chi AM Mattocks, Clin Pharmacol Ther 1981 29 516 521 10.1038/clpt.1981.72 7471619
16. Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load. RS Pedersen H Bentzen JN Bech O Nyvad EB Pedersen, Kidney Int 2003 63 1417 1425 10.1046/j.1523-1755.2003.00858.x 12631357
17. Down-regulation of urinary AQP2 and unaffected response to hypertonic saline after 24 hours of fasting in humans. J Starklint JN Bech EB Pedersen, Kidney Int 2005 67 1010 1018 10.1111/j.1523-1755.2005.00164.x 15698439
18. Mechanisms to concentrate the urine: an opinion. ML Halperin KS Kamel MS Oh, Curr Opin Nephrol Hypertens 2008 17 416 422 10.1097/MNH.0b013e328304b3f5 18660679
19. The physiology of urinary concentration: an update. JM Sands HE Layton, Semin Nephrol 2009 29 178 195 10.1016/j.semnephrol.2009.03.008 19523568
20. Decrease in urinary excretion of aquaporin-2 associated with impaired urinary concentrating ability in diabetic nephropathy. T Nakamura T Saito I Kusaka M Higashiyama S Nagasaka S Ishibashi SE Ishikawa, Nephron 2002 92 445 448 10.1159/000063285 12218327
21. Evaluation of renal concentrating and diluting ability. BB Davis TV Zenser, Clin Lab Med 1993 13 131 134 8462256
22. A Comparison between creatinine and cystatin C-based GFR equations in renal transplantation. A Zahran M Mabood Qureshi Shoker, Nephrol Dial Transplant 2007 22 2659 2668 10.1093/ndt/gfm243 17470455
23. Prediction of creatinine clearance from serum creatinine. DW Cockcroft MH Gault, Nephron 1976 16 31 41 10.1159/000180580 1244564
24. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. AS Levey JP Bosch JB Lewis T Greene N Rogers D Roth, Ann Intern Med 1999 130 461 470 10075613
25. A new equation to estimate glomerular filtration rate. AS Levey LA Stevens CH Schmid YL Zhang AF Castro HI Feldman JW Kusek P Eggers F Van Lente T Greene J Coresh, Ann Intern Med 2009 150 604 612 19414839
26. Urinary concentration and dilution in the aging kidney. JM Sands, Semin Nephrol 2009 29 579 586 10.1016/j.semnephrol.2009.07.004 20006789
27. Downregulation of renal vasopressin V2 receptor and aquaporin-2 expression parallels age-associated defects in urine concentration. Y Tian R Serino JG Verbalis, Am J Physiol Renal Physiol 2004 287 797 805 10.1152/ajprenal.00403.2003 15213068
28. Angiotensin II upregulates the expression of vasopressin V2 mRNA in the inner medullary collecting duct of the rat. NL Wong JK Tsui, Metabolism 2003 52 290 295 10.1053/meta.2003.50047 12647265
29. Angiotensin II AT1 receptor blockade decreases vasopressin-induced water reabsorption and AQP2 levels in NaCl-restricted rats. TH Kwon J Nielsen MA Knepper J Frokiaer S Nielsen, Am J Physiol Renal Physiol 2005 288 673 F684 10.1152/ajprenal.00304.2004 15585668
30. Decreased expression of aquaporin water channels in denervated rat kidney. J Lee K Yoo SW Kim KH Jung SK Ma YK Lee WY Kim J Kim KC Choi, Nephron Physiol 2006 103 170 178 10.1159/000092918 (Pubitemid 44114513)
31. Increased AQP2 targeting in primary cultured IMCD cells in response to angiotensin II through AT1 receptor. YJ Lee IK Song KJ Jang J Nielsen J Frøkiaer S Nielsen TH Kwon, Am J Physiol Renal Physiol 2007 292 340 F350 10.1152/ajprenal.00090.2006 16896188
32. Long-term aldosterone treatment induces decreased apical but increased basolateral expression of AQP2 in CCD of rat kidney. S de Seigneux J Nielsen ET Olesen H Dimke TH Kwon J Frøkiaer S Nielsen, Am J Physiol Renal Physiol 2007 293 87 F99 10.1152/ajprenal.00431.2006 17376764
33. Vasopressin directly regulates cyst growth in polycystic kidney disease. X Wang Y Wu CJ Ward PC Harris VE Torres, J Am Soc Nephrol 2008 19 102 108 10.1681/ASN.2007060688 18032793
34. Role of vasopressin antagonists. VE Torres, Clin J Am Soc Nephrol 2008 4 1212 1218 10.2215/CJN.05281107
35. Novel targets for the treatment of autosomal dominant polycystic kidney disease. FA Belibi CL Edelstein, Expert Opin Investig Drugs 2010 19 315 328 10.1517/13543781003588491 20141351